955997-87-2

Usage

Uses

Used in Pharmaceutical Industry:
N,N'-bis(4-isobutoxybenzyl)urea is used as an impurity in the preparation of Pimavanserin (P441800) for the treatment of Parkinson’s disease and psychosis. Its presence in the synthesis process is crucial for the development of this drug, which targets specific serotonin receptors to alleviate symptoms associated with these conditions.

Upstream product

• 4734-09-2 1-[4-(2-methylpropyloxy)phenyl]methanamine 
• 639863-75-5 1-(isocyanatomethyl)-4-(2-methylpropoxy)benzene 
• 359878-47-0 N- [(4-fluorophenyl)methyl]-1-methylpiperidin-4-amine 
• 18962-07-7 4-isobutoxybenzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 140-75-0 para-fluorobenzylamine 
• 1030513-44-0 4-isobutoxybenzamide 
• 5203-15-6 4-(2-methylpropoxy)benzonitrile 
• 767-00-0 4-cyanophenol 
• 459-57-4 4-fluorobenzaldehyde 
• 1194-02-1 4-fluorobenzonitrile 

Relevant academic research and scientific papers

An improved process for the preparation of pimavanserin tartrate

A practical synthetic route to pimavanserin tartrate, in which the target compound was obtained with 99.84% purity and in 46% total yield via a 5-step synthesis starting from 4-hydroxybenzaldehyde and (4-fluorophenyl)methanamine, is reported. The main advantages of the route include inexpensive starting materials, mild reaction conditions and an acceptable overall yield.

PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN

The present disclosure relates to novel, safe and efficient processes for the synthesis of Pimavanserin and salts thereof, as well as novel intermediates that can be used in these processes.

Tartaric acid pimavanserin impurities and preparation method thereof

The invention discloses tartaric acid pimavanserin impurities, namely N-(4-isobutoxy benzyl) diphenyl aminodiphthalate (impurity A), 4-isobutoxy benzyl carbonic acid phenyl ester (impurity B), 4-fluorobenzyl (1-methylpiperidine-4-yl) carbonic acid-4-isobutoxy benzyl ester (impurity C) and N-( isobutoxy benzyl)-N'-(4-fluorobenzyl) urea (impurity E). In addition, the invention further discloses a preparation method of tartaric acid pimavanserin impurities A, B, C and E and an N,N'-bis(4-isobutoxy benzyl) urea (impurity D). Through application of the tartaric acid pimavanserin impurities as reference substances in research on the quality of the tartaric acid pimavanserin intermediate, a crude drug and a compound preparation thereof, a solid foundation is laid for research on the quality of tartaric acid pimavanserin.